A medical isotope is an isotope used in medicine. The first uses of isotopes in medicine were in radiopharmaceuticals, and this is still the most common use. However more recently, separated stable isotopes have also come into use.
In general, most isotope suppliers are not direct manufacturers because the direct manufacturers come from nuclear power plants. Isotope suppliers are generally authorized by the National Nuclear Energy Agency or signed an exclusive agreement. In addition, in the market, subsidiaries of the National Nuclear Energy Corporation are also the largest suppliers.
Highlights
The global Medical Isotopes market was valued at US$ 808.7 million in 2022 and is anticipated to reach US$ 1005.7 million by 2029, witnessing a CAGR of 3.7% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Many medical products today are sterilised by gamma rays from a Co-60 source, a technique which generally is much cheaper and more effective than steam heat sterilisation. The disposable syringe is an example of a product sterilised by gamma rays. Because it is a 'cold' process radiation can be used to sterilise a range of heat-sensitive items such as powders, ointments, and solutions, as well as biological preparations such as bone, nerve, and skin to be used in tissue grafts. Large-scale irradiation facilities for gamma sterilisation are installed in many countries. Smaller gamma irradiators, often utilising Cs-137, having a longer half-life, are used for treating blood for transfusions and for other medical applications. Sterilisation by radiation has several benefits. It is safer and cheaper because it can be done after the item is packaged. The sterile shelf-life of the item is then practically indefinite provided the seal is not broken. Apart from syringes, medical products sterilised by radiation include cotton wool, burn dressings, surgical gloves, heart valves, bandages, plastic, and rubber sheets and surgical instruments. Within the United States and other parts of the developed world, the trend has been to reduce the use of Co-60. And many U.S. hospitals have shifted to generating highly energetic beams with accelerator technology for such therapy. But much of the developing world still employs Co-60 mainly because of the capital costs associated with switching to alternative non-radioactive source technologies.
North America is the largest consumer by regions. Europe is the second largest with 26% market share. Asia Pacific s the following consumption region with 15% consumption market share. While the U.S. produces a significant number of the isotopes used by researchers, industry and the medical community, the U.S. is dependent upon foreign sources for many. Historically the U.S. provided almost all of the isotopes that were required for domestic consumption or, in special cases, acquired them from long-time allies. But beginning in the 1990鈥檚 other governments began to view the isotope industry as a high tech growth industry, and subsidized the production and sale of isotopes, targeting U.S. companies. The result is that U.S. industry has been switching its buying from the U.S. and DOE to foreign sources of supply.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Medical Isotopes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medical Isotopes.
The Medical Isotopes market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Medical Isotopes market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Medical Isotopes companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
NRG
NTP Radioisotopes
JSC Isotope
ANSTO
IRE
Nordion
Curium Pharma
Cambridge Isotope Laboratories
Eckert & Ziegler Strahlen
Polatom
Center of Molecular Research
China National Nuclear Corporation
Urenco
LANL
Shanghai Engineering Research Center
IDB Holland
NHTC
Linde
ORNL
SI Science
Segment by Type
Stable Isotopes
Radioisotopes
Segment by Application
Nuclear Therapy
Equipment Radioactive Source
Diagnosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Medical Isotopes companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Medical Isotopes 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stable Isotopes
1.2.3 Radioisotopes
1.3 麻豆原创 by Application
1.3.1 Global Medical Isotopes 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Nuclear Therapy
1.3.3 Equipment Radioactive Source
1.3.4 Diagnosis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Medical Isotopes 麻豆原创 Perspective (2018-2029)
2.2 Medical Isotopes Growth Trends by Region
2.2.1 Global Medical Isotopes 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Medical Isotopes Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Medical Isotopes Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Medical Isotopes 麻豆原创 Dynamics
2.3.1 Medical Isotopes Industry Trends
2.3.2 Medical Isotopes 麻豆原创 Drivers
2.3.3 Medical Isotopes 麻豆原创 Challenges
2.3.4 Medical Isotopes 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Medical Isotopes Players by Revenue
3.1.1 Global Top Medical Isotopes Players by Revenue (2018-2023)
3.1.2 Global Medical Isotopes Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Medical Isotopes 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Medical Isotopes Revenue
3.4 Global Medical Isotopes 麻豆原创 Concentration Ratio
3.4.1 Global Medical Isotopes 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Medical Isotopes Revenue in 2022
3.5 Medical Isotopes Key Players Head office and Area Served
3.6 Key Players Medical Isotopes Product Solution and Service
3.7 Date of Enter into Medical Isotopes 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Medical Isotopes Breakdown Data by Type
4.1 Global Medical Isotopes Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Medical Isotopes Forecasted 麻豆原创 Size by Type (2024-2029)
5 Medical Isotopes Breakdown Data by Application
5.1 Global Medical Isotopes Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Medical Isotopes Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Medical Isotopes 麻豆原创 Size (2018-2029)
6.2 North America Medical Isotopes 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Medical Isotopes 麻豆原创 Size by Country (2018-2023)
6.4 North America Medical Isotopes 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Medical Isotopes 麻豆原创 Size (2018-2029)
7.2 Europe Medical Isotopes 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Medical Isotopes 麻豆原创 Size by Country (2018-2023)
7.4 Europe Medical Isotopes 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Medical Isotopes 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Medical Isotopes 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Medical Isotopes 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Medical Isotopes 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Medical Isotopes 麻豆原创 Size (2018-2029)
9.2 Latin America Medical Isotopes 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Medical Isotopes 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Medical Isotopes 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Medical Isotopes 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Medical Isotopes 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Medical Isotopes 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Medical Isotopes 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 NRG
11.1.1 NRG Company Detail
11.1.2 NRG Business Overview
11.1.3 NRG Medical Isotopes Introduction
11.1.4 NRG Revenue in Medical Isotopes Business (2018-2023)
11.1.5 NRG Recent Development
11.2 NTP Radioisotopes
11.2.1 NTP Radioisotopes Company Detail
11.2.2 NTP Radioisotopes Business Overview
11.2.3 NTP Radioisotopes Medical Isotopes Introduction
11.2.4 NTP Radioisotopes Revenue in Medical Isotopes Business (2018-2023)
11.2.5 NTP Radioisotopes Recent Development
11.3 JSC Isotope
11.3.1 JSC Isotope Company Detail
11.3.2 JSC Isotope Business Overview
11.3.3 JSC Isotope Medical Isotopes Introduction
11.3.4 JSC Isotope Revenue in Medical Isotopes Business (2018-2023)
11.3.5 JSC Isotope Recent Development
11.4 ANSTO
11.4.1 ANSTO Company Detail
11.4.2 ANSTO Business Overview
11.4.3 ANSTO Medical Isotopes Introduction
11.4.4 ANSTO Revenue in Medical Isotopes Business (2018-2023)
11.4.5 ANSTO Recent Development
11.5 IRE
11.5.1 IRE Company Detail
11.5.2 IRE Business Overview
11.5.3 IRE Medical Isotopes Introduction
11.5.4 IRE Revenue in Medical Isotopes Business (2018-2023)
11.5.5 IRE Recent Development
11.6 Nordion
11.6.1 Nordion Company Detail
11.6.2 Nordion Business Overview
11.6.3 Nordion Medical Isotopes Introduction
11.6.4 Nordion Revenue in Medical Isotopes Business (2018-2023)
11.6.5 Nordion Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Detail
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Medical Isotopes Introduction
11.7.4 Curium Pharma Revenue in Medical Isotopes Business (2018-2023)
11.7.5 Curium Pharma Recent Development
11.8 Cambridge Isotope Laboratories
11.8.1 Cambridge Isotope Laboratories Company Detail
11.8.2 Cambridge Isotope Laboratories Business Overview
11.8.3 Cambridge Isotope Laboratories Medical Isotopes Introduction
11.8.4 Cambridge Isotope Laboratories Revenue in Medical Isotopes Business (2018-2023)
11.8.5 Cambridge Isotope Laboratories Recent Development
11.9 Eckert & Ziegler Strahlen
11.9.1 Eckert & Ziegler Strahlen Company Detail
11.9.2 Eckert & Ziegler Strahlen Business Overview
11.9.3 Eckert & Ziegler Strahlen Medical Isotopes Introduction
11.9.4 Eckert & Ziegler Strahlen Revenue in Medical Isotopes Business (2018-2023)
11.9.5 Eckert & Ziegler Strahlen Recent Development
11.10 Polatom
11.10.1 Polatom Company Detail
11.10.2 Polatom Business Overview
11.10.3 Polatom Medical Isotopes Introduction
11.10.4 Polatom Revenue in Medical Isotopes Business (2018-2023)
11.10.5 Polatom Recent Development
11.11 Center of Molecular Research
11.11.1 Center of Molecular Research Company Detail
11.11.2 Center of Molecular Research Business Overview
11.11.3 Center of Molecular Research Medical Isotopes Introduction
11.11.4 Center of Molecular Research Revenue in Medical Isotopes Business (2018-2023)
11.11.5 Center of Molecular Research Recent Development
11.12 China National Nuclear Corporation
11.12.1 China National Nuclear Corporation Company Detail
11.12.2 China National Nuclear Corporation Business Overview
11.12.3 China National Nuclear Corporation Medical Isotopes Introduction
11.12.4 China National Nuclear Corporation Revenue in Medical Isotopes Business (2018-2023)
11.12.5 China National Nuclear Corporation Recent Development
11.13 Urenco
11.13.1 Urenco Company Detail
11.13.2 Urenco Business Overview
11.13.3 Urenco Medical Isotopes Introduction
11.13.4 Urenco Revenue in Medical Isotopes Business (2018-2023)
11.13.5 Urenco Recent Development
11.14 LANL
11.14.1 LANL Company Detail
11.14.2 LANL Business Overview
11.14.3 LANL Medical Isotopes Introduction
11.14.4 LANL Revenue in Medical Isotopes Business (2018-2023)
11.14.5 LANL Recent Development
11.15 Shanghai Engineering Research Center
11.15.1 Shanghai Engineering Research Center Company Detail
11.15.2 Shanghai Engineering Research Center Business Overview
11.15.3 Shanghai Engineering Research Center Medical Isotopes Introduction
11.15.4 Shanghai Engineering Research Center Revenue in Medical Isotopes Business (2018-2023)
11.15.5 Shanghai Engineering Research Center Recent Development
11.16 IDB Holland
11.16.1 IDB Holland Company Detail
11.16.2 IDB Holland Business Overview
11.16.3 IDB Holland Medical Isotopes Introduction
11.16.4 IDB Holland Revenue in Medical Isotopes Business (2018-2023)
11.16.5 IDB Holland Recent Development
11.17 NHTC
11.17.1 NHTC Company Detail
11.17.2 NHTC Business Overview
11.17.3 NHTC Medical Isotopes Introduction
11.17.4 NHTC Revenue in Medical Isotopes Business (2018-2023)
11.17.5 NHTC Recent Development
11.18 Linde
11.18.1 Linde Company Detail
11.18.2 Linde Business Overview
11.18.3 Linde Medical Isotopes Introduction
11.18.4 Linde Revenue in Medical Isotopes Business (2018-2023)
11.18.5 Linde Recent Development
11.19 ORNL
11.19.1 ORNL Company Detail
11.19.2 ORNL Business Overview
11.19.3 ORNL Medical Isotopes Introduction
11.19.4 ORNL Revenue in Medical Isotopes Business (2018-2023)
11.19.5 ORNL Recent Development
11.20 SI Science
11.20.1 SI Science Company Detail
11.20.2 SI Science Business Overview
11.20.3 SI Science Medical Isotopes Introduction
11.20.4 SI Science Revenue in Medical Isotopes Business (2018-2023)
11.20.5 SI Science Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
NRG
NTP Radioisotopes
JSC Isotope
ANSTO
IRE
Nordion
Curium Pharma
Cambridge Isotope Laboratories
Eckert & Ziegler Strahlen
Polatom
Center of Molecular Research
China National Nuclear Corporation
Urenco
LANL
Shanghai Engineering Research Center
IDB Holland
NHTC
Linde
ORNL
SI Science
听
听
*If Applicable.
